Literature DB >> 14552836

Leucine-rich repeats and pathogen recognition in Toll-like receptors.

Jessica K Bell1, Gregory E D Mullen, Cynthia A Leifer, Alessandra Mazzoni, David R Davies, David M Segal.   

Abstract

Toll-like receptors (TLRs) are the major cell-surface initiators of inflammatory responses to pathogens. They bind a wide variety of pathogenic substances through their ectodomains (ECDs). Here, we ask: what is the structural basis for this interaction? Toll-like receptor ECDs comprise 19-25 tandem copies of a motif known as the leucine-rich repeat (LRR). No X-ray structure of a TLR-ECD is currently available but there are several high-resolution LRR-containing proteins that can be used to model TLRs. We suggest that the basic framework of TLRs is a horseshoe-shaped solenoid that contains an extensive beta-sheet on its concave surface, and numerous ligand-binding insertions. Together, these insertions and the beta-sheet could provide a binding surface that is 10-fold greater in area than binding surfaces in antibodies and T-cell receptors.

Mesh:

Substances:

Year:  2003        PMID: 14552836     DOI: 10.1016/s1471-4906(03)00242-4

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  188 in total

1.  The structure of SDS22 provides insights into the mechanism of heterodimer formation with PP1.

Authors:  Meng S Choy; Nicolas Bolik-Coulon; Tara L Archuleta; Wolfgang Peti; Rebecca Page
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2018-11-30       Impact factor: 1.056

2.  Intragenic suppression of a trafficking-defective brassinosteroid receptor mutant in Arabidopsis.

Authors:  Youssef Belkhadir; Amanda Durbak; Michael Wierzba; Robert J Schmitz; Andrea Aguirre; Rene Michel; Scott Rowe; Shozo Fujioka; Frans E Tax
Journal:  Genetics       Date:  2010-05-10       Impact factor: 4.562

Review 3.  Important aspects of Toll-like receptors, ligands and their signaling pathways.

Authors:  Z L Chang
Journal:  Inflamm Res       Date:  2010-07-01       Impact factor: 4.575

4.  Positive selection pressure within teleost Toll-like receptors tlr21 and tlr22 subfamilies and their response to temperature stress and microbial components in zebrafish.

Authors:  Arvind Y M Sundaram; Sonia Consuegra; Viswanath Kiron; Jorge M O Fernandes
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

Review 5.  Mucins and toll-like receptors: kith and kin in infection and cancer.

Authors:  Shikha Tarang; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-02-03       Impact factor: 8.679

Review 6.  The critical role of toll-like receptors--From microbial recognition to autoimmunity: A comprehensive review.

Authors:  Maximiliano Javier Jiménez-Dalmaroni; M Eric Gerswhin; Iannis E Adamopoulos
Journal:  Autoimmun Rev       Date:  2015-08-20       Impact factor: 9.754

7.  Identification and functional characterization of nonmammalian Toll-like receptor 20.

Authors:  Danilo Pietretti; Marleen Scheer; Inge R Fink; Nico Taverne; Huub F J Savelkoul; Herman P Spaink; Maria Forlenza; Geert F Wiegertjes
Journal:  Immunogenetics       Date:  2013-12-11       Impact factor: 2.846

8.  Toll-like receptor 9 and 21 have different ligand recognition profiles and cooperatively mediate activity of CpG-oligodeoxynucleotides in zebrafish.

Authors:  Da-Wei Yeh; Yi-Ling Liu; Yin-Chiu Lo; Chiou-Hwa Yuh; Guann-Yi Yu; Jeng-Fan Lo; Yunping Luo; Rong Xiang; Tsung-Hsien Chuang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

9.  A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition.

Authors:  Jin Liu; Congfeng Xu; Li-Chung Hsu; Yunping Luo; Rong Xiang; Tsung-Hsien Chuang
Journal:  Mol Immunol       Date:  2009-12-08       Impact factor: 4.407

Review 10.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.